There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cryolife (CRY – Research Report) and Genocea Biosciences (GNCA – Research Report) with bullish sentiments.
In a report released today, Michael Matson from Needham reiterated a Buy rating on Cryolife, with a price target of $38.00. The company’s shares closed last Thursday at $27.39.
According to TipRanks.com, Matson is a 5-star analyst with an average return of 17.4% and a 69.4% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Cardiovascular Systems.
Currently, the analyst consensus on Cryolife is a Moderate Buy with an average price target of $34.67.
Genocea Biosciences (GNCA)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences today and set a price target of $9.00. The company’s shares closed last Thursday at $2.02, close to its 52-week low of $1.80.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 28.2% and a 47.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Genocea Biosciences is a Strong Buy with an average price target of $7.00, a 241.5% upside from current levels. In a report issued on July 14, Robert W. Baird also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.